Actavis builds brand business, generates generics growth
This article was originally published in Scrip
Actavis hosted its annual investor day on 31 January to lay the groundwork for 2014 and beyond with a focus on expanding its brand name portfolio while growing the generics business that makes up the largest segment of its revenue, which is expected to total $10bn this year.
You may also be interested in...
Private Company Edition: Arvelle, insitro, AbCellera and the University of Michigan have something in common – they each attracted more than $100m in venture capital investment.
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.